(Q37810593)

23 August 2017

Lipid lowering for secondary prevention of cardiovascular disease in older adults (English)

1 reference

23 August 2017

cardiovascular disease

1 reference

Joseph E Thomas

1

1 reference

23 August 2017

Andrew M Tershakovec

2

1 reference

23 August 2017

Charlotte Jones-Burton

3

1 reference

23 August 2017

Reza A Sayeed

4

1 reference

23 August 2017

JoAnne M Foody

5

1 reference

23 August 2017

1 December 2010

1 reference

23 August 2017

1 reference

23 August 2017

27

1 reference

23 August 2017

12

1 reference

23 August 2017

959-972

1 reference

https://scigraph.springernature.com/pub.10.2165/11539550-000000000-00000

23 August 2017

0 references

cites work

High blood cholesterol in elderly men and the excess risk for coronary heart disease

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11539550-000000000-00000

Estimating treatment benefits for the elderly: the effect of competing risks

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11539550-000000000-00000

Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11539550-000000000-00000

Analyses of cancer data from three ezetimibe trials

21 January 2018

1 reference

12 December 2020

Health outcome priorities among competing cardiovascular, fall injury, and medication-related symptom outcomes

1 reference

12 December 2020

High-dose atorvastatin after stroke or transient ischemic attack

1 reference

12 December 2020

High density lipoprotein cholesterol and the risk of stroke in elderly men: the Honolulu heart program

1 reference

12 December 2020

The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III.

1 reference

12 December 2020

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

12 December 2020

Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia

1 reference

12 December 2020

Low cholesterol, mortality, and quality of life in old age during a 39-year follow-up

1 reference

12 December 2020

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes

1 reference

12 December 2020

Striated muscle safety of ezetimibe/simvastatin (Vytorin).

1 reference

12 December 2020

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

1 reference

12 December 2020

ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins

1 reference

12 December 2020

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

1 reference

12 December 2020

An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design

1 reference

12 December 2020

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

1 reference

12 December 2020

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

1 reference

12 December 2020

Safety considerations with gastrointestinally active lipid-lowering drugs

1 reference

12 December 2020

Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-cont

1 reference

12 December 2020

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).

1 reference

12 December 2020

Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data

1 reference

12 December 2020

Dyslipidemia as a risk factor at elderly age.

1 reference

12 December 2020

Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence

1 reference

12 December 2020

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial

1 reference

12 December 2020

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis

1 reference

12 December 2020

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

12 December 2020

Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials

1 reference

12 December 2020

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

1 reference

12 December 2020

Simvastatin with or without ezetimibe in familial hypercholesterolemia

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial

1 reference

12 December 2020

Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study

1 reference

12 December 2020

The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review

1 reference

12 December 2020

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

12 December 2020

Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia

1 reference

12 December 2020

Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox

1 reference

12 December 2020

Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

Coronary drug project: experience with niacin. Coronary Drug Project Research Group

1 reference

12 December 2020

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

12 December 2020

Safety of aggressive lipid management

1 reference

12 December 2020

Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack

1 reference

12 December 2020

Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis

1 reference

12 December 2020

Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop

1 reference

12 December 2020

Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins

1 reference

12 December 2020

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

12 December 2020

Do coronary heart disease risk factors measured in the elderly have the same predictive roles as in the middle aged. Comparisons of relative and attributable risks

1 reference

12 December 2020

An assessment of statin safety by neurologists.

1 reference

12 December 2020

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

12 December 2020

The paradox of cholesterol and stroke

1 reference

12 December 2020

Is it time for a cardiovascular primary prevention trial in the elderly?

1 reference

12 December 2020

Key factors associated with the under-prescription of statins in elderly coronary heart disease patients: Results from the ELIAGE and ELICOEUR surveys

1 reference

12 December 2020

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

12 December 2020

10.2165/11539550-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

23 August 2017

0 references

1 reference